Related Experiment Video
Updated: Jul 17, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
Junjie Teng1,2, Kai Zhou1, Dongxiao Lv1
1Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Abstract:
Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study.
Insights
This case study explores PTEN mutations in lung cancer. A patient with advanced lung adenocarcinoma resistant to anti-PD-1 immunotherapy was found to have a PTEN mutation, suggesting it may predict treatment resistance.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Lung cancer is a leading global cancer. Advanced non-small cell lung cancer (NSCLC) treatments include targeted therapy and immunotherapy.
- The role of PTEN mutations in NSCLC immunotherapy response remains unclear.
Observation:
- A case of stage IV lung adenocarcinoma with an ERBB2 mutation is presented.
- The patient received Nivolumab (anti-PD-1 immunotherapy) after progression on chemotherapy and Afatinib but showed no response.
- Next-generation sequencing revealed a PTEN mutation after Nivolumab treatment.
Findings:
- The presence of a PTEN mutation, identified post-immunotherapy, may indicate resistance to anti-PD-1 therapy in lung adenocarcinoma.
- PTEN mutations could potentially serve as a biomarker for predicting immunotherapy outcomes.
Implications:
- This finding suggests PTEN mutations might be a secondary event contributing to immunotherapy resistance in NSCLC.
- Further research is needed to elucidate the complex relationship between PTEN mutations and immunotherapy efficacy in lung adenocarcinoma.
